Glenmark Pharma is currently trading at Rs. 286.00, up by 4.45 points or 1.58% from its previous closing of Rs. 281.55 on the BSE.
The scrip opened at Rs. 284.00 and has touched a high and low of Rs. 290.10 and Rs. 281.55 respectively. So far 94,756 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 389.75 on 07-Dec-2010 and a 52 week low of Rs. 241.60 on 28-Feb-2011.
Last one week high and low of the scrip stood at Rs. 290.10 and Rs. 273.25 respectively. The current market cap of the company is Rs. 7629.78 crore.
The promoters holding in the company stood at 48.32% while Institutions and Non-Institutions held 37.92% and 13.75% respectively.
Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India has discovered and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark’s Biologics Research Centre located in Switzerland.
The disease areas primarily targeted by GBR 401 are lymphomas and leukemia’s of B-cell origin. Lymphomas are cancers originating from the lymphatic system. Non-Hodgkin’s lymphoma (NHL), a type of B cell lymphoma, is the most common form of blood cancer.
GBR 401 shows great promise to emerge as a valuable therapeutic option to treat patients affected with B-cell malignancies. GBR 401 has demonstrated strong anti-tumour potency and anti-proliferative apoptotic activity in several in-vito and in-vivo studies. CD19 is known to be expressed earlier and more broadly in B-cell development than CD20, the latter being the target of the world’s second largest selling anti-cancer biotech product rituximab whose annual 2010 sales were in excess of $6 billion.
No comments:
Post a Comment